[
  {
    "ts": null,
    "headline": "Gilead Sciences to Present at Upcoming Investor Conferences",
    "summary": "FOSTER CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",
    "url": "https://finnhub.io/api/news?id=340ddab472d4c675d7c6a4bbaca9223b3c171ee364a93fdb54db64478fc7f0b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771880700,
      "headline": "Gilead Sciences to Present at Upcoming Investor Conferences",
      "id": 139188022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",
      "url": "https://finnhub.io/api/news?id=340ddab472d4c675d7c6a4bbaca9223b3c171ee364a93fdb54db64478fc7f0b4"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
    "url": "https://finnhub.io/api/news?id=66b417b8404a82f3f931c48f50de5af21d2e9613a9f37532b8f91c21671a95a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771880489,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 139187961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
      "url": "https://finnhub.io/api/news?id=66b417b8404a82f3f931c48f50de5af21d2e9613a9f37532b8f91c21671a95a7"
    }
  },
  {
    "ts": null,
    "headline": "Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update",
    "summary": "Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24,",
    "url": "https://finnhub.io/api/news?id=ad4bb7ed8365662c57749febf4f521cb845ffc0c1b6205292948bcc7e7a59985",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771880460,
      "headline": "Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update",
      "id": 139188024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24,",
      "url": "https://finnhub.io/api/news?id=ad4bb7ed8365662c57749febf4f521cb845ffc0c1b6205292948bcc7e7a59985"
    }
  },
  {
    "ts": null,
    "headline": "Equities, Treasury Yields Fall Intraday as Markets Weigh New Trump Tariffs",
    "summary": "US benchmark equity indexes and Treasury yields fell intraday as investors assessed new tariffs anno",
    "url": "https://finnhub.io/api/news?id=000b7bf31c5e1898777f2decd1562075b91c106d669a2e5dd60164aa0587ba9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771873814,
      "headline": "Equities, Treasury Yields Fall Intraday as Markets Weigh New Trump Tariffs",
      "id": 139187138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes and Treasury yields fell intraday as investors assessed new tariffs anno",
      "url": "https://finnhub.io/api/news?id=000b7bf31c5e1898777f2decd1562075b91c106d669a2e5dd60164aa0587ba9b"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Shares of Arcellx Are Up Almost 80% Today",
    "summary": "Shares of biotech firm Arcellx are jumping on a down day for stocks.",
    "url": "https://finnhub.io/api/news?id=73d1a43b910972b9c3790a8487dd681da8b314db00d15ed97fb01aee1e5e2a94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771871189,
      "headline": "Here's Why Shares of Arcellx Are Up Almost 80% Today",
      "id": 139187330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Shares of biotech firm Arcellx are jumping on a down day for stocks.",
      "url": "https://finnhub.io/api/news?id=73d1a43b910972b9c3790a8487dd681da8b314db00d15ed97fb01aee1e5e2a94"
    }
  },
  {
    "ts": null,
    "headline": "Gilead acquires CAR-T specialist Arcellx for $7.8bn",
    "summary": "Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.",
    "url": "https://finnhub.io/api/news?id=08c7e659cf93a44d6893d099a6529c84baa401ae474bd3211da3f8bf67328595",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771865087,
      "headline": "Gilead acquires CAR-T specialist Arcellx for $7.8bn",
      "id": 139186475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.",
      "url": "https://finnhub.io/api/news?id=08c7e659cf93a44d6893d099a6529c84baa401ae474bd3211da3f8bf67328595"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion",
    "summary": "All three major US stock indexes were down in late-morning trading Monday, as investors weigh the co",
    "url": "https://finnhub.io/api/news?id=e4d61d0d6adf7fd1318d9b4fde5ed228d1d0339d823c6afdf9bc2c1a19fab8a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771863360,
      "headline": "Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion",
      "id": 139186364,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were down in late-morning trading Monday, as investors weigh the co",
      "url": "https://finnhub.io/api/news?id=e4d61d0d6adf7fd1318d9b4fde5ed228d1d0339d823c6afdf9bc2c1a19fab8a6"
    }
  },
  {
    "ts": null,
    "headline": "This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It.",
    "summary": "Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.",
    "url": "https://finnhub.io/api/news?id=6f8a6e084be04241e5bedf7c7035fa7fadc023af8833e36fc80f088ac63e2393",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771860420,
      "headline": "This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It.",
      "id": 139186477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.",
      "url": "https://finnhub.io/api/news?id=6f8a6e084be04241e5bedf7c7035fa7fadc023af8833e36fc80f088ac63e2393"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J",
    "summary": "Gilead Sciences is buying Arcellx for $7.8 billion. The companies are already working together on a multiple myeloma drug.",
    "url": "https://finnhub.io/api/news?id=3d5feb0aa8d3e40768b93d8c0383426e27b992c41dfacaf1206b31e139d8fe60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771860380,
      "headline": "Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J",
      "id": 139185146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences is buying Arcellx for $7.8 billion. The companies are already working together on a multiple myeloma drug.",
      "url": "https://finnhub.io/api/news?id=3d5feb0aa8d3e40768b93d8c0383426e27b992c41dfacaf1206b31e139d8fe60"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
    "summary": "? Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ↘️ Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://finnhub.io/api/news?id=6adc7ab400ce9225ffacd064418fc9532cca6d1c1c3066289ae6b99aad5741eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771857667,
      "headline": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
      "id": 139185136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "? Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ↘️ Novo Nordisk (NVO), (DK:NOVO.",
      "url": "https://finnhub.io/api/news?id=6adc7ab400ce9225ffacd064418fc9532cca6d1c1c3066289ae6b99aad5741eb"
    }
  },
  {
    "ts": null,
    "headline": "Alphabet, Nvidia upgraded: Wall Street's top analyst calls",
    "summary": "Alphabet, Nvidia upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=58abd29852f1d0017343572242e72cb9542b03aa309715e386a1f6f5a8fc72bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771857179,
      "headline": "Alphabet, Nvidia upgraded: Wall Street's top analyst calls",
      "id": 139185068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Alphabet, Nvidia upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=58abd29852f1d0017343572242e72cb9542b03aa309715e386a1f6f5a8fc72bc"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal",
    "summary": "Gilead Sciences (GILD) on Monday agreed to acquire cancer therapy developer Arcellx (ACLX) in a deal",
    "url": "https://finnhub.io/api/news?id=ca35908dc29879651a19eff5dd96e905d2100260d265d752e3b12455f51f027c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771855721,
      "headline": "Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal",
      "id": 139185247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) on Monday agreed to acquire cancer therapy developer Arcellx (ACLX) in a deal",
      "url": "https://finnhub.io/api/news?id=ca35908dc29879651a19eff5dd96e905d2100260d265d752e3b12455f51f027c"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Medical Companies This Earnings Season?",
    "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
    "url": "https://finnhub.io/api/news?id=7884f2c87cb0f77ade9a77c1c8a5dc1a6fdc8ee80361015fff97667392aff78d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771855620,
      "headline": "What's in Store for These 5 Medical Companies This Earnings Season?",
      "id": 139185147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
      "url": "https://finnhub.io/api/news?id=7884f2c87cb0f77ade9a77c1c8a5dc1a6fdc8ee80361015fff97667392aff78d"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Digests Supreme Court Tariff Ruling, Driving Premarket Losses for US Equity Futures",
    "summary": "US equity futures were down ahead of Monday's opening bell as investors digested a Supreme Court dec",
    "url": "https://finnhub.io/api/news?id=2bccfb3f29197aebf25303e7ed336652fbd24c5a11c9a58573d86b134ab503dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771855567,
      "headline": "Wall Street Digests Supreme Court Tariff Ruling, Driving Premarket Losses for US Equity Futures",
      "id": 139185249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "US equity futures were down ahead of Monday's opening bell as investors digested a Supreme Court dec",
      "url": "https://finnhub.io/api/news?id=2bccfb3f29197aebf25303e7ed336652fbd24c5a11c9a58573d86b134ab503dd"
    }
  },
  {
    "ts": null,
    "headline": "Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition",
    "summary": "Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition",
    "url": "https://finnhub.io/api/news?id=3550e85720e73a8bffef26b5c505943378a91aea0c944bdf33302dc76939bb93",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771854644,
      "headline": "Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition",
      "id": 139186951,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3550e85720e73a8bffef26b5c505943378a91aea0c944bdf33302dc76939bb93"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Renewed Trade Doubts",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5%, and the actively t",
    "url": "https://finnhub.io/api/news?id=e14ac548df14a88b24961069e887f71b0412f4905581d01be5991ed4d8ce86e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771854631,
      "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Renewed Trade Doubts",
      "id": 139183739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5%, and the actively t",
      "url": "https://finnhub.io/api/news?id=e14ac548df14a88b24961069e887f71b0412f4905581d01be5991ed4d8ce86e1"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal",
    "summary": "Gilead Sciences announced an agreement to acquire Arcellx for $115 in cash per share, a 79% premium to the biotech's Friday close.  Gilead will pay an additional $5 per share if sales of its top drug, anito-cell, total at least $6 billion through 2029.  ACLX stock vaulted higher in early Monday stock market action, while GILD dipped slightly.",
    "url": "https://finnhub.io/api/news?id=50ef26f19504e2026e8340e2f4ef079e70209e21fce93eca09179ace3a2f9307",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771854258,
      "headline": "Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal",
      "id": 139183692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences announced an agreement to acquire Arcellx for $115 in cash per share, a 79% premium to the biotech's Friday close.  Gilead will pay an additional $5 per share if sales of its top drug, anito-cell, total at least $6 billion through 2029.  ACLX stock vaulted higher in early Monday stock market action, while GILD dipped slightly.",
      "url": "https://finnhub.io/api/news?id=50ef26f19504e2026e8340e2f4ef079e70209e21fce93eca09179ace3a2f9307"
    }
  },
  {
    "ts": null,
    "headline": "This Biotech Jumped 78%. Gilead Sciences Is Buying It.",
    "summary": "Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.",
    "url": "https://finnhub.io/api/news?id=c159bdcd7dfa7c0769f52e5bfccd378d9c81be2c622922d6fa5319d224f30c50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771853940,
      "headline": "This Biotech Jumped 78%. Gilead Sciences Is Buying It.",
      "id": 139185250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.",
      "url": "https://finnhub.io/api/news?id=c159bdcd7dfa7c0769f52e5bfccd378d9c81be2c622922d6fa5319d224f30c50"
    }
  },
  {
    "ts": null,
    "headline": "Gilead pays $7.8bn to take full control of promising multiple myeloma therapy",
    "summary": "Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright ownership of a CAR T-cell therapy that could be approved by US regulators before the end of this...",
    "url": "https://finnhub.io/api/news?id=b94414abbb3db4f759a53b2b828fe1c19c5ca585f87d6f5705d72d0ecfdfe997",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771852560,
      "headline": "Gilead pays $7.8bn to take full control of promising multiple myeloma therapy",
      "id": 139183741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright ownership of a CAR T-cell therapy that could be approved by US regulators before the end of this...",
      "url": "https://finnhub.io/api/news?id=b94414abbb3db4f759a53b2b828fe1c19c5ca585f87d6f5705d72d0ecfdfe997"
    }
  },
  {
    "ts": null,
    "headline": "Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion",
    "summary": "Feb 23 () - Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the ‌biopharma company said on Monday, as it looks to strengthen its lineup ‌of cancer treatments.",
    "url": "https://finnhub.io/api/news?id=9ae72c9d8c20112036c6ab810af86eb68cd81fef60b9e0fde547df200da6096a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771851283,
      "headline": "Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion",
      "id": 139183742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Feb 23 () - Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the ‌biopharma company said on Monday, as it looks to strengthen its lineup ‌of cancer treatments.",
      "url": "https://finnhub.io/api/news?id=9ae72c9d8c20112036c6ab810af86eb68cd81fef60b9e0fde547df200da6096a"
    }
  },
  {
    "ts": null,
    "headline": "This Biotech Stock Is Surging 78%. Gilead Sciences Agrees to Buy It.",
    "summary": "Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.",
    "url": "https://finnhub.io/api/news?id=902a97a1ede6364164694aa3e414be9a6c3d6d2115da315bd2749ac6bcd5fbc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771850520,
      "headline": "This Biotech Stock Is Surging 78%. Gilead Sciences Agrees to Buy It.",
      "id": 139183743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.",
      "url": "https://finnhub.io/api/news?id=902a97a1ede6364164694aa3e414be9a6c3d6d2115da315bd2749ac6bcd5fbc5"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
    "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
    "url": "https://finnhub.io/api/news?id=41f0d909132c61a9c64972c7a016cf90be2bb65250e557a211873bca7593cf84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771850116,
      "headline": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
      "id": 139183638,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
      "url": "https://finnhub.io/api/news?id=41f0d909132c61a9c64972c7a016cf90be2bb65250e557a211873bca7593cf84"
    }
  },
  {
    "ts": null,
    "headline": "What Gilead Is Getting Through The Acquisition Of Arcellx",
    "summary": "What Gilead Is Getting Through The Acquisition Of Arcellx",
    "url": "https://finnhub.io/api/news?id=6f058e6a81d8e1f75d4e54ce8910941b4208381db1bf7d7f05df6c4b5049e3a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771847216,
      "headline": "What Gilead Is Getting Through The Acquisition Of Arcellx",
      "id": 139185670,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6f058e6a81d8e1f75d4e54ce8910941b4208381db1bf7d7f05df6c4b5049e3a9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion",
    "summary": "Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.",
    "url": "https://finnhub.io/api/news?id=9a1d8733fd1314a15243fa8951318db1f00f57537d21db77aab0d195f8b1e052",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771846560,
      "headline": "Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion",
      "id": 139183745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.",
      "url": "https://finnhub.io/api/news?id=9a1d8733fd1314a15243fa8951318db1f00f57537d21db77aab0d195f8b1e052"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
    "summary": "? American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
    "url": "https://finnhub.io/api/news?id=6348325e68d87034b6baf1aa52bd9b839aeee05cf344928def011007645b619d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771841184,
      "headline": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
      "id": 139183030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "? American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
      "url": "https://finnhub.io/api/news?id=6348325e68d87034b6baf1aa52bd9b839aeee05cf344928def011007645b619d"
    }
  },
  {
    "ts": null,
    "headline": "Gilead to acquire Arcellx for $7.8 billion",
    "summary": "Feb 23 () - Gilead Sciences said ‌on Monday it ‌will buy cancer therapy ​developer Arcellx for an implied equity value of $7.8 ‌billion, ⁠sending shares of Arcellx climbing ⁠77.",
    "url": "https://finnhub.io/api/news?id=0578e43e56f13fc04bda6f4e6cafa3b4543ac082d14535a45ebe11535508585c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771845341,
      "headline": "Gilead to acquire Arcellx for $7.8 billion",
      "id": 139183092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Feb 23 () - Gilead Sciences said ‌on Monday it ‌will buy cancer therapy ​developer Arcellx for an implied equity value of $7.8 ‌billion, ⁠sending shares of Arcellx climbing ⁠77.",
      "url": "https://finnhub.io/api/news?id=0578e43e56f13fc04bda6f4e6cafa3b4543ac082d14535a45ebe11535508585c"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel",
    "summary": "FOSTER CITY, Calif. & REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur",
    "url": "https://finnhub.io/api/news?id=6a118e73e53389561d437c92a28473656b968d5215c27232e6c622646526c751",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771844460,
      "headline": "Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel",
      "id": 139183093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif. & REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur",
      "url": "https://finnhub.io/api/news?id=6a118e73e53389561d437c92a28473656b968d5215c27232e6c622646526c751"
    }
  },
  {
    "ts": null,
    "headline": "UK companies seek deeper ties with Europe as Trump tariffs fuel uncertainty, business groups say",
    "summary": "U.S. President Donald Trump's latest tariffs measures have thrust British businesses into fresh uncertainty.",
    "url": "https://finnhub.io/api/news?id=c741d7523a00107b7c4bf031685065ada1d5dda6fb563de5892d002a3502b643",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771841274,
      "headline": "UK companies seek deeper ties with Europe as Trump tariffs fuel uncertainty, business groups say",
      "id": 139185966,
      "image": "https://image.cnbcfm.com/api/v1/image/108268503-1771859066418-gettyimages-2247050683-UK_PORT.jpeg?v=1771859098&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "U.S. President Donald Trump's latest tariffs measures have thrust British businesses into fresh uncertainty.",
      "url": "https://finnhub.io/api/news?id=c741d7523a00107b7c4bf031685065ada1d5dda6fb563de5892d002a3502b643"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug",
    "summary": "Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer.",
    "url": "https://finnhub.io/api/news?id=0fb2b2799fdea15810a89377e0419f1ff7a5043c8a677f0151b7478d7b646e5a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771836688,
      "headline": "Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug",
      "id": 139184125,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/23/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpeg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer.",
      "url": "https://finnhub.io/api/news?id=0fb2b2799fdea15810a89377e0419f1ff7a5043c8a677f0151b7478d7b646e5a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy",
    "summary": "The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.",
    "url": "https://finnhub.io/api/news?id=26b9a48386e9487333b00cd45d30cd546745fc458935b95004323548ad2a55b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771832940,
      "headline": "Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy",
      "id": 139185251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.",
      "url": "https://finnhub.io/api/news?id=26b9a48386e9487333b00cd45d30cd546745fc458935b95004323548ad2a55b6"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more",
    "summary": "These are the stocks posting the largest moves in premarket trading.",
    "url": "https://finnhub.io/api/news?id=8e777de2bedbd4f2c9385d854949383f19add9ce36af48f10b7d2a23b469768a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771831948,
      "headline": "Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more ",
      "id": 139185842,
      "image": "https://image.cnbcfm.com/api/v1/image/108261536-1770233397984-Side_by_Side_template.jpg?v=1770233491&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "These are the stocks posting the largest moves in premarket trading. ",
      "url": "https://finnhub.io/api/news?id=8e777de2bedbd4f2c9385d854949383f19add9ce36af48f10b7d2a23b469768a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Announced Definitive Agreement To Acquire Arcellx For $115 Per Share In Cash And $5 Per Share Contingent Value Right",
    "summary": "Gilead Sciences Announced Definitive Agreement To Acquire Arcellx For $115 Per Share In Cash And $5 Per Share Contingent Value Right",
    "url": "https://finnhub.io/api/news?id=c47d05eb55f9a2809c49157db3a1ee140465cc9ee0dda018aa16ac6bd328ffaa",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771830294,
      "headline": "Gilead Sciences Announced Definitive Agreement To Acquire Arcellx For $115 Per Share In Cash And $5 Per Share Contingent Value Right",
      "id": 139184127,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c47d05eb55f9a2809c49157db3a1ee140465cc9ee0dda018aa16ac6bd328ffaa"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial",
    "summary": "Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn't meet its primary target.",
    "url": "https://finnhub.io/api/news?id=adb46c1fb7d8aa3447f4b0c93366d841ae4fcf0e75cdd60bdb482a92eb48a14e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771822420,
      "headline": "Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial",
      "id": 139185849,
      "image": "https://image.cnbcfm.com/api/v1/image/108226736-1763385463345-gettyimages-2244595163-DENMARK_DOUSTDAR.jpeg?v=1771844458&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn't meet its primary target. ",
      "url": "https://finnhub.io/api/news?id=adb46c1fb7d8aa3447f4b0c93366d841ae4fcf0e75cdd60bdb482a92eb48a14e"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has […]",
    "url": "https://finnhub.io/api/news?id=3e8941e4e0a328b1ff8e4bcededceb68b94489afec37578712c8087fe8eb0918",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771813429,
      "headline": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
      "id": 139180603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has […]",
      "url": "https://finnhub.io/api/news?id=3e8941e4e0a328b1ff8e4bcededceb68b94489afec37578712c8087fe8eb0918"
    }
  }
]